699-03-6

Usage

Uses

Used in Pharmaceutical Industry:
(4-BROMOBENZYL)METHYLAMINE is used as a building block for the synthesis of various pharmaceuticals due to its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
(4-BROMOBENZYL)METHYLAMINE is used as a precursor in the preparation of agrochemicals, playing a role in the creation of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
(4-BROMOBENZYL)METHYLAMINE is utilized as an intermediate in organic synthesis for the production of a wide array of organic compounds, leveraging its reactive bromine atom and benzene ring.
Used in Coordination Chemistry:
(4-BROMOBENZYL)METHYLAMINE is employed as a ligand, participating in the formation of coordination compounds that have applications in various areas, including catalysis and material science.
Used in Enzyme-Catalyzed Reaction Studies:
(4-BROMOBENZYL)METHYLAMINE serves as a substrate in the investigation of enzyme-catalyzed reactions, providing insights into enzymatic mechanisms and the potential for biocatalytic applications.

InChI:InChI=1/C8H10BrN/c1-10-6-7-2-4-8(9)5-3-7/h2-5,10H,6H2,1H3/p+1

Upstream product

• 6274-57-3 (4-bromobenzyl)dimethylamine 
• 1122-91-4 4-bromo-benzaldehyde 
• 74-89-5 methylamine 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 589-17-3 p-bromobenzyl chloride 
• 86402-04-2 N-(p-bromobenzylidene)methylamine 
• 35003-56-6 1-(4-bromophenyl)-N-methylmethanimine 

Downstream Products

• 98736-50-6 N-nitroso-N-(4-bromobenzyl)methylamine 
• 160528-76-7 4-hydroxy-4-(4-methylaminomethyl-phenyl)-cyclohexanone-ethylene-ketal 
• 1174903-48-0 3-[[(4-bromobenzyl)-methyl-amino]methyl]-5-(pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one 
• 1262999-64-3 2-((4-bromobenzyl)(methyl)amino)benzaldehyde 
• 1444877-86-4 1-(4-bromophenyl)-N-(3-tert-butoxybenzyl)-N-methylmethanamine 
• 1444877-76-2 3-[N-(4-bromobenzyl)-N-methylaminomethyl]phenol 
• 41690-89-5 (4-butoxy-benzyl)-methyl-amine 
• 283173-50-2 Rucaparib 

Relevant academic research and scientific papers

Copper-Mediated Radiosynthesis of [18F]Rucaparib

The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful approach features an aldehydic boronic ester precursor that is subjected to reductive amination post-18F-labeling and affords [18F]rucaparib with an activity yield of 11% ± 3% (n = 3) and a molar activity (Am) up to 30 GBq/μmol. Preliminary in vitro studies are presented.

METHODS AND INTERMEDIATES FOR PREPARING RUCAPARIB

The present invention relates to a process for preparing rucaparib or pharmaceutically acceptable salts thereof. It also provides novel intermediates that may be converted into rucaparib or pharmaceutically acceptable salts thereof.

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Smooth isoindolinone formation from isopropyl carbamates via bischler-napieralski-type cyclization

Isopropyl carbamates derived from benzylamines provide isoindolinones by treatment with phosphorus pentoxide at room temperature. Utility of this Bischler-Napieralski-type cyclization and a new mechanism involving a carbamoyl cation for rationalization of this smooth conversion are discussed.

Chemoselective reductive nucleophilic addition to tertiary amides, secondary amides, and N-methoxyamides

As the complexity of targeted molecules increases in modern organic synthesis, chemoselectivity is recognized as an important factor in the development of new methodologies. Chemoselective nucleophilic addition to amide car-bonyl centers is a challenge because classical methods require harsh reaction conditions to overcome the poor elec-trophilicity of the amide carbonyl group. We have successfully developed a reductive nucleophilic addition of mild nu-cleophiles to tertiary amides, secondary amides, and N-methoxyamides that uses the Schwartz reagent [Cp2ZrHCl]. The reaction took place in a highly chemoselective fashion in the presence of a variety of sensitive functional groups, such as methyl esters, which conventionally require protection prior to nucleophilic addition. The reaction will be applicable to the concise synthesis of complex natural alkaloids from readily available amide groups.

NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS

The invention relates to novel bis-amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.

Highly enantioselective synthesis of tetrahydroquinolines via cobalt(II)-catalyzed tandem 1,5-hydride transfer/cyclization

A chiral catalyst prepared from N,N′-dioxide and Co(BF 4)2·6H2O was applied in the asymmetric hydride transfer initiated cyclization reaction, giving optically active tetrahydroquinolines in good yields with high enantioselectivities under mild reaction conditions. Meanwhile, in light of the absolute configuration of the product, a possible working model was proposed to explain the origin of the activation and asymmetric induction.

LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

NOVEL BIS-AMIDES AS ANTIMALARIAL AGENTS

The invention relates to novel bis-amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.

Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations

3H-1,3,4-Oxadiazol-2-one derivatives were synthesized and tested for their in vitro antimycobacterial activity. Oxadiazolone derivatives showed an interesting antimycobacterial activity against the reference strain of Mycobacterium tuberculosis H37Rv. Molecular modeling investigations were performed and showed that the active compounds possess all necessary features to target the protein active site of the mycobacterial cytochrome P450-dependent sterol 14α-demethylase in the sterol biosynthesis pathway as the calculated free energy of binding were in agreement with the corresponding MIC values.